$Sangamo Therapeutics (SGMO.US)$
Should be interesting to see what we get in up front.  It's been given Accelerated Approval by FDA so BLA  will be filed next year sometime once we get final patient data.  I'm guessing 100 to 200 million up front.

$Sangamo Therapeutics (SGMO.US)$
Roche terminated their Hemo A gene therapy, so that's good for us.  Fabry deal by end of week hopefully would be nice Christmas Present.

$Sernova Corp (SVA.CA)$
Cell pouch isles after 5 years are as good as normal healthy pancreas!!@

$Sangamo Therapeutics (SGMO.US)$
Fabry gene therapy has almost no side effects and requires no steroids or immunosuppressive therapy at all so far.
This is rare in gene therapy.

$Sangamo Therapeutics (SGMO.US)$
Pfizer presents P3 data at ASH next week December 9th
And Fabry deal discussions are well underway after getting Acellerated Approval from FDA recently. A couple of nice near term catalysts that should move the stock.

$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy
Benzinga· 3 mins ago

$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...

$Oncolytics Biotech (ONCY.US)$
Earnings report and updates tomorrow morning before opening.  It's overdue. We're they waiting for something to announce?? GLTA.